Trial reportMolecular imaging and biology
Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT.
Trial report in Molecular imaging and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 57 citations in OpenAlex.
- Comparison of [European journal of nuclear medicine and molecular imaging · 2026Trial
- False Positive Findings ofMolecular imaging and radionuclide therapy · 2025Article
- Targeting the tumour cell surface in advanced prostate cancer.Nature reviews. Urology · 2025Review
- PET/CT and Conventional Imaging for the Assessment of Neuroendocrine Prostate Cancer: A Systematic Review.Cancers · 2023Review
- PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies.European radiology · 2023Review
- Molecular Imaging in Recurrent Prostate Cancer Presented as a Mixed Small Neuroendocrine Tumor/Acinar Adenocarcinoma.Nuclear medicine and molecular imaging · 2023Article
- Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Imaging of Neuroendocrine Prostatic Carcinoma.Cancers · 2021Review
- Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review.Journal of clinical medicine · 2021Review
- Clinical considerations for the management of androgen indifferent prostate cancer.Prostate cancer and prostatic diseases · 2021Review
- New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer.Frontiers in chemistry · 2020Review
- Somatostatin receptors as a new active targeting sites for nanoparticles.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2018Review
- [Neuroendocrine prostate cancer].Der Pathologe · 2018Article
- [Neuroendocrine prostate cancer].Der Urologe. Ausg. A · 2017Article
- Low-Dose Molecular Ultrasound Imaging with E-Selectin-Targeted PBCA Microbubbles.Molecular imaging and biology · 2016Article
- Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients.Annals of translational medicine · 2015Article
- Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate.Cancer biotherapy & radiopharmaceuticals · 2014Article
- Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced "in Vivo" byWorld journal of oncology · 2014Article
- PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors.TheScientificWorldJournal · 2014Article
- Prospective of ⁶⁸Ga-radiopharmaceutical development.Theranostics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess DOTATOC-affine somatostatin receptor expression in advanced prostate cancer and its bone metastases with regard to DOTATOC-mediated receptor therapies, using a Ga-68-DOTATOC PET/CT. PROCEDURES: Twenty consecutive patients with advanced prostate cancer underwent bone scintigraphy, followed by Ga-68-DOTATOC PET/CT within 3 weeks. Through side-by-side comparison with bone scintigraphy, the number of visible bone metastases on PET was determined. In addition, in cases of visible metastases, the maximum standard uptake value (SUV(max)) of Ga-68-DOTATOC was measured in the metastases and in normal bone. In patients who did not undergo a prostatectomy (n = 12), the SUV(max) was additionally measured in the prostate and in adjacent tissue. For focal lesions, the difference in SUV(max) (Delta SUV(max)) between the metastases and normal bone was calculated. For patients still having their prostate, a Delta SUV(max) between the prostate and its adjacent tissue was calculated.
resultsSixty four of 216 metastases (30%) were visible in 13 patients with focal metastases. Of six patients with diffuse metastases (superscan), one showed diffuse metastases, three showed a total of ten focal metastases, and two showed no correlate on PET. One patient with a neuroendocrine prostate cancer showed no correlate on PET. The maximum Delta SUV(max) between metastases and normal bone was 4.9 (mean = 1.6 +/- 0.9) and between the prostate and adjacent tissue 5.9 (mean = 2.8 +/- 1.6).
conclusionsIn prostate cancer and its bone metastases, DOTATOC-affine somatostatin receptors (subtype 2 and 5) can be visualized with Ga-68-DOTATOC PET/CT. But their expression is so weak that other conjugates should be tested for receptor-mediated therapies which are better at addressing the prostate cancer-specific somatostatin receptor subtypes 1 and 4-or even other receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.